NEW CANAAN, CT--(Marketwire - May 15, 2008) - An abstract submitted to the Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30-June 3, Chicago, Illinois, entitled "Phase Ia Safety and Pharmacokinetic Study of Oral NV-196 in Patients with Solid Tumours" is now available at www.asco.org (Abstract# 14615). The abstract reports on a human clinical study of oral triphendiol which demonstrated a good safety profile and successful pharmacokinetics. The trial was conducted by Professor Paul Mainwaring at the Brisbane Mater Adult Hospital in Brisbane, Australia.
